In fact, selective ETAR blockade by the experimental drug atrasentan has been shown to delay progression of hormone-refractory prostate adenocarcinoma [115] and enhance the effect of paclitaxel/docetaxel used for treatment of prostate cancer [116] in patients. The gene discussed is EDNRA; the disease is prostate carcinoma.